

Abatacept (powder)

Cat. No.:	HY-108829A
CAS No.:	332348-12-6
Target:	CTLA-4
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases^{[1][2][3]}.

REFERENCES

- [1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. *J Allergy Clin Immunol Pract.* 2019 Jun 22.
- [2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. *J Pharmacokinet Pharmacodyn.* 2013 Dec;40(6):701-12.
- [3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. *Arthritis Rheumatol.* 2016 Mar;68(3):627-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA